IBA installs the first new-generation cyclotron in Russia for radiopharmaceuticals production

Louvain-la-Neuve, July 11, 2018 IBA (Belgium) - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, celebrated the installation of the first IBA Cyclone® KIUBE cyclotron in the Russian Federation at the Nuclear Diagnostics Unit of the Proton Therapy Center at Dr. Berezin Medical Institute in St. Petersburg. This new-generation cyclotron will offer positron emission tomography for more than 15 000 oncological patients annually.

Positron emission tomography is a modern diagnostic method that helps identify a pathology, differentiate a tumor and evaluate its dynamics by monitoring biochemical changes in tissues during treatment. The method is based on the use of minimal, safe doses of radiopharmaceuticals.

"Cyclone® KIUBE was developed by IBA in 2016. It has the highest beam current on the market of 300 µA and energy of 18 MeV. The cyclotron provides radioisotopes of the maximum activity and has the highest production capacity ever reached by a PET cyclotron. IBA concentrated 30 years of experience and innovation in the new Cyclone® KIUBE that delivers outstanding performances", explains Mr. Jean-Michel Geets, IBA product manager.

In comparison with market standards, Cyclone® KIUBE is compact and has a wide range of upgrade options for its performance increase. The cyclotron has a unique technology for Ga-68 isotope production, which is necessary for the diagnosis of prostate cancer and other neoplasms.

Medical Institute St. Petersburg will be one of the first sites to benefit of this new technology.

"This new-generation cyclotron will give us the opportunity to expand the range of radiopharmaceuticals and cover the needs of all the three our PET/CT diagnostic centers in St. Petersburg", said Mr. Arkady Stolpner, Chairman of the Board of Directors of Dr. Berezin Medical Institute.

The event was attended by:
- Mr. Hans Timbremont, Consul General of Belgium in St. Petersburg;
- Mr. Gerard Seghers, Economic and Commercial Counselor of the Embassy of Belgium;
- Mr. Nikolay Tsed, Head of Primorsky District Administration;
- Mr. Oliver Holderbaum, Head of Global Sales, IBA Radiopharma Solutions;
- Mr. Kirill Makarenko, General Director of IBA Russia & CIS;
- Mr. Arkady Stolpner, Chairman of the Board of Directors, Dr. Berezin Medical Institute;
- Mr. Pavel Borisenko, Deputy Chairman of the Committee on Investments of St. Petersburg;

***Ends***
About IBA Radiopharma Solutions
Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers. To date IBA RadioPharma Solutions has installed more than 270 cyclotrons on five continents.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Dr. Sergey Berezin Medical Institute (MIBS)
Dr. Sergey Berezin Medical Institute is Russia's largest private health investor. The company comprises a network of 93 radiation diagnosis centers in 68 cities of Russia, Ukraine and Armenia; a network of nuclear (PET/CT) diagnostic centers; it is an oncology center with the widest range of medical equipment for radiotherapy; the first Proton Therapy Center in Russia and CIS countries.

IBA
Tel.: +7 495 648 69 00 (ext.1001)
Mobile: +7 916 040 40 14
E-mail: info-russia@iba-group.com
www.iba-worldwide.com; www.iba-radiopharmasolutions.ru